203. Alegre M-L, Depierreux M, Florquin S, et al. Nephrotoxicity of anti-CD3 monoclonal antibodies [in French]. *Nephrologie* 1991; 12: 42-5
204. Batiuk TD, Bennett WM, Norman DJ. Cytokine nephropathy during antilymphocyte therapy. *Transplant Proc* 1993 Apr; 25 Suppl. 1: 27-30
205. First MR, Schroeder TJ, Hariharan S. OKT3-induced cytokine-release syndrome: renal effects (cytokine nephropathy). *Transplant Proc* 1993 Apr; 25 Suppl. 1: 25-6
206. Dussol B, Brunet P, Vacher-Coponat H, et al. Haemolytic uraemic syndrome in a renal transplant recipient during OKT3 therapy. *Nephrol Dial Transplant* 1994; 9 (8): 1191-3
207. Doutrelepont J-M, Abramowicz D, Florquin S, et al. Early recurrence of hemolytic uremic syndrome in a renal transplant recipient during prophylactic OKT3 therapy. *Transplantation* 1992; 53: 1378-9
208. Bemelman FJ, Buysmann S, Yong SL, et al. Biphasic granulocytopenia after administration of the first dose of OKT3 [abstract]. *Kidney Int* 1995 Apr; 47: 1218
209. Burke III GW, Vercellotti GM, Simmons RL, et al. Reversible pancytopenia following OKT3. Use in the context of multi-drug immunosuppression for kidney allografting. *Transplantation* 1989 Sep; 48: 403-7
210. Vasquez EM, Pollak R. Effect of OKT3 therapy on cyclosporine blood levels [abstract]. *Pharmacotherapy* 1995 Jan-Feb; 15: 118-9
211. Chan GL, Weinstein SS, Wright CE, et al. Encephalopathy associated with OKT3 administration. Possible interaction with indomethacin. *Transplantation* 1991 Jul; 52: 148-50
212. Doutrelepont JM, Abramowicz D, Borre B, et al. Prophylactic OKT3: practical considerations for the prevention of first-dose reactions. *Transplant Proc* 1993 Apr; 25 Suppl. 1: 45-6
213. Dantal J, Souillou J-P. Use of monoclonal antibodies in human transplantation. *Curr Opin Immunol* 1991 Oct; 3: 740-7
214. Krensky AM, Clayberger C. Transplantation immunology. *Pediatr Clin North Am* 1994 Aug; 41: 819-39

Correspondence: *Michelle I. Wilde*, Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand.

Erratum

Vol. 51, No. 2, page 314: In section 5.2, the second sentence in the third paragraph should read: 'Dialyser clearances of urea . . . (mean dosage 4335IU 3 times weekly) . . .'.

[Dunn CJ, Markham A. Epoetin beta: a review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure. *Drugs* 1996 Feb; 51 (2): 299-318]